Instructions for use, contraindications, composition of Pentasa

Pentasa is a medication to treat ulcerative colitis.

Therapeutic of Pentasa

NSAIDs — salicylic acid derivatives

The nosological classification (ICD-10)

K50 Crohn’s disease [regional enteritis]

K51 Ulcerative colitis

K62.8.1 * Proctitis

Active ingredient: 500 mg of mesalazine

Excipients: povidone; ethyl cellulose; magnesium stearate; talc; MSC 750 mg

Pentas. Indication: Ulcerative colitis, including proctitis, Crohn's disease. Contraindications: Hypersensitivity (including to salicylates or other components of the preparation.); expressed human liver and kidneys.

Pentas. Indication: Ulcerative colitis, including proctitis, Crohn’s disease. Contraindications: Hypersensitivity (including to salicylates or other components of the preparation.); expressed human liver and kidneys.

Pharmachologic effect of Pentasa

Mode of action — anti-inflammatory.

Reduces the formation of leukotrienes and cytokinins, neutralizes free radicals, inhibits leukocyte chemotaxis.

Indications for use of Pentasa

Ulcerative colitis, including proctitis, Crohn’s disease.

Contraindications of Pentasa

Hypersensitivity (including to salicylates or other components of the preparation.); expressed human liver and kidneys.

Contraindications of Pentasa

Absolute:

Hemorrhagic diathesis; Severe renal and / or hepatic impairment; Gastric ulcer or duodenal ulcer; Pregnancy (2-4 weeks before delivery); The period of breastfeeding (lactation); Children under 2 years (for tablets), up to 6 years (pellet); suppositories and suspension are contraindicated for use in pediatric patients due to insufficient data; Hypersensitivity to mesalazine and / or other components.

The relative (a drug used with caution due to the increased risk of complications): Allergy to salicylates (possible hypersensitivity reaction to sulfasalazine); Violations of lung function, including asthma; Renal / liver failure mild to moderate severity (increased systemic concentration of mesalazine and reduced elimination rate increases the risk of kidney damage); Pregnancy (except for the period of 2-4 weeks before birth) (the drug is used according to indications, only in case of exceeding the potential benefit to the mother of the possible risk of adverse effects to the fetus).

Pregnancy and breast-feeding

During pregnancy and lactation period is prescribed only in cases where the positive effects outweigh the risk of possible side effects.

The recommended dosing regimen for adults:

Ulcerative colitis: during exacerbation — 2 pcs. 2-4 times a day; maintenance treatment — 1 pc. 2-3 times per day;

Crohn’s disease: an exacerbation of — 2-4 pcs. 4 times a day; maintenance treatment — 2-4 pcs. 2 times a day, or 2-3 pcs. 3 times per day.

Children selected individual dose of mesalazine, usually at the rate of 0.02-0.03 g / kg of body weight per day in divided doses.

Side effects of Pentasa

The feeling of discomfort in the abdomen, nausea, vomiting, headache, diarrhea, skin rash in the form of hives or eczema; rarely — muscle aches and joint pain, temporary hair loss, dysfunction of liver and kidneys, pericarditis, myocarditis, pancreatitis, changes in the blood count (leukopenia, granulocytopenia, thrombocytopenia, anemia).

Bodies of hematopoiesis: rarely — anemia, leukopenia, eosinophilia, granulocytopenia, thrombocytopenia, pancytopenia, agranulocytosis; Immune system: very rarely — hypersensitivity reactions, angioedema, drug fever; Nervous system: rare — dizziness; very rare — Benign intracranial hypertension, peripheral neuropathy; Cardiovascular system: rarely — pericarditis, myocarditis; Respiratory system: very rarely — cough, dyspnea, allergic alveolitis, lung infiltration, pulmonary eosinophilia, pneumonia, bronchoconstriction; The digestive system: often — diarrhea, abdominal pain, nausea, vomiting, flatulence; rarely — pancreatitis, increased amylase; very rarely — an exacerbation of colitis symptoms; Hepatobiliary system: very rarely — increased levels of bilirubin and liver enzymes, liver toxicity (hepatotoxicity, hepatitis, hepatic failure, cirrhosis); Skin: often — eczema, urticaria; very rarely — reversible alopecia, photosensitivity; Musculoskeletal system: very rarely — arthralgia, myalgia; Urinary system: very rarely — nephrotic syndrome, interstitial nephritis, transient renal failure, changes in urine color; Other: often — fever, headache; Reactions at the injection site (suspension suppositories): rarely — pain and irritation in the anal area.